MariMed reports FY2025 revenue of $159.8M, net loss widens to $14.5M, adjusted EBITDA down to $16.9M

MARIMED INC.

FY2025 revenue $159.8M, up from $157.7M in FY2024; Q4 revenue $41.7M vs $38.9M.
GAAP net loss $14.5M in FY2025 vs $12.4M; Non-GAAP adjusted EBITDA $16.9M, down from $19.3M.
Wholesale revenue increased 11%; distribution reached 85% of dispensaries in core markets.
Betty's Eddies ranked #1 edible in MA, MD, DE, IL; restructured Series B debt, extending maturity 4.6 years.
CEO cites growth drivers for 2026: Delaware adult-use, Maine brand licensing, new Columbus OH dispensary.

Key facts

Extracted from this filing and checked against the source text.

Earnings Releases SEC 8-K Item 2.02 confidence 0.95

MARIMED INC. reported fourth quarter and year ended December 31, 2025 results: revenue $159.8 million, net income GAAP Net loss $ (14.5).

Period: fourth quarter and year ended December 31, 2025
Revenue: $159.8 million
Net income: GAAP Net loss $ (14.5)
Result: reported results

Exact text from the filing

Adjusted EBITDA for the sixth consecutive year, reflecting the strength of its branded product portfolio and disciplined operational execution. 2025 Highlights • Revenue of $159.8 million • Sixth consecutive year of positive Adjusted EBITDA • Wholesale revenue increased 11% • Distribution expanded to 85% of dispensaries in core markets • Betty’s Eddies ranked #1

View on SEC.gov

Browse all earnings releases →

MARIMED INC. filing history →

Source: SEC EDGAR

accession 0001522767-26-000027

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.